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INTRODUCTION
The development of the embryonic vasculature involves the
remodeling of a primitive capillary plexus into a more
organized, highly branched vessel network (Risau and
Flamme, 1995). The primary vascular plexi are laid down
during the process of vasculogenesis, in which endothelial
precursors aggregate to form blood islands in the yolk sac
and endothelial strands in the embryo proper (Risau and
Flamme, 1995). Angiogenesis, the adaptive morphogenetic
transformation of these simple networks, results in organized,
highly branched, hierarchical networks of large and small
vessels. Remodeling during angiogenesis occurs through the
sprouting of new branches, the pruning of existing branches,
the fusion of neighboring capillaries and the splitting of
individual capillaries (intussuception), as well as endothelial
proliferation, apoptosis and migration (reviewed by Patan,
2000; Yancopoulos et al., 2000). Integral to this process is the
recruitment of supporting pericytes (Schor et al., 1995) and
smooth muscle cells (Oh et al., 2000; Yancopoulos et al., 2000;
Folkman and D’Amore, 1996).
Angiogenesis involves a complex series of reciprocal
interactions between the endothelial cells of the developing
blood vessels and neighboring cells. Perivascular
mesenchymal cells provide endothelial cells with signals such
as vascular endothelial growth factor (VEGF) (Carmeliet et al.,
1996; Ferrara et al., 1996) and angiopoietin 1 (Ang1) (Davis
et al., 1996; Suri et al., 1996; Sato et al., 1995; Dumont et al.,
1994). In turn, endothelial cells send signals of their own, such
as platelet-derived growth factor (PDGF) (Hellstrom et al.,
1999; Hirschi et al., 1999), transforming growth factor b
(TGFb ) (Goumans et al., 1999; Pepper, 1997; Oshima et al.,
1996; Dickson et al., 1995) and neuregulin (Kramer et al.,
1996; Meyer and Birchmeier, 1995; Marchionni et al., 1993),
to surrounding support cells (reviewed by Flamme et al., 1997;
Hanahan, 1997). Endothelial cells must also interact with one
another, coordinating vessel integrity, identity, growth and
remodeling via such molecules as Delta-4 (Krebs et al., 2000;
Shutter et al., 2000), integrin avb3 (Friedlander et al., 1995;
Brooks et al., 1994) and VE-cadherin (Gory-Faure et al., 1999;
Breier et al., 1996). Therefore, both endothelial-support cell
and inter-endothelial communication are required for proper
vessel assembly (Gale and Yancopoulos, 1999; Hanahan, 1997;
Folkman and D’Amore, 1996; Risau and Flamme, 1995).
EPH receptor tyrosine kinases and their transmembrane
ligands, the ephrins (Wilkinson, 2000), have recently been
shown to be expressed in and around the developing circulatory
system (reviewed by Adams and Klein, 2000). Several studies
have implicated ephrin signaling in endothelial cell behavior
and angiogenesis (Adams et al., 2001; Helbling et al., 2000;
Adams et al., 1999; Gerety et al., 1999; Stein et al., 1998; Wang
et al., 1998; Daniel et al., 1996; Stein et al., 1996). EphrinB2
(Efnb2 – Mouse Genome Informatics) is specifically expressed
in arterial endothelial cells, and ephrinB2 homozygous mutant
mice die at E9.5 with severe cardiovascular defects (Adams et
al., 1999; Wang et al., 1998). To date, ephrinB2 is the only
ephrin ligand whose knockout shows an angiogenic phenotype
(Adams et al., 1999). Deletion of the ephrinB2 cytoplasmic
domain yields an identical vascular phenotype, consistent with
the notion that this transmembrane ligand functions in reverse
signaling (Adams et al., 2001).
Initial studies suggested that the main ligand function of
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EphrinB2, a transmembrane ligand of EphB receptor
tyrosine kinases, is specifically expressed in arteries. In
ephrinB2 mutant embryos, there is a complete arrest of
angiogenesis. However, ephrinB2 expression is not
restricted to vascular endothelial cells, and it has been
proposed that its essential function may be exerted in
adjacent mesenchymal cells. We have generated mice in
which ephrinB2 is specifically deleted in the endothelium
and endocardium of the developing vasculature and heart.
We find that such a vascular-specific deletion of ephrinB2
results in angiogenic remodeling defects identical to those
seen in the conventional ephrinB2 mutants. These data
indicate that ephrinB2 is required specifically in
endothelial and endocardial cells for angiogenesis, and that
ephrinB2 expression in perivascular mesenchyme is not
sufficient to compensate for the loss of ephrinB2 in these
vascular cells.
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ephrinB2 is exerted in the arterial endothelium, where it
mediates signaling to veins via EphB4 (Ephb4 – Mouse
Genome Informatics), a receptor more abundantly expressed
on venous endothelial cells (Gerety et al., 1999; Wang et al.,
1998). Consistent with this notion, Ephb4 mutant mice show
angiogenic defects similar or identical to those in ephrinB2–/–
mice (Gerety et al., 1999). However, in contrast to Ephb4,
which is restricted to the cardiovascular system, expression of
ephrinB2 is not restricted to endothelial cells, but is also found
in mesenchymal cells, pericytes and vascular smooth muscle
cells surrounding sites of active angiogenesis (Gale et al., 2001;
Shin et al., 2001; Adams et al., 1999; Wang et al., 1998). These
observations suggested that ephrinB2 might mediate support
cell to endothelial cell communication, as well as inter-
endothelial interactions (Adams et al., 1999; Gale and
Yancopoulos, 1999; Gerety et al., 1999). Consistent with this,
recent studies in mouse (Adams et al., 1999) and Xenopus
(Helbling et al., 2000) have attributed a role to mesenchyme-
derived ephrinB2 signals in restricting blood vessel growth to
the intersomitic space. In these experiments, however, ephrin
signaling was disrupted throughout the embryo, obscuring its
essential site of action.
We were interested in determining whether endothelial
ephrinB2 expression is essential for angiogenesis, or if
ephrinB2 derived from perivascular mesenchyme is sufficient
to drive vascular remodeling. We therefore constructed a
conditional allele of ephrinB2 that can be excised by the
expression of Cre recombinase (Cre) in a tissue of interest
(Nagy, 2000; Orban et al., 1992). Endothelial-specific deletion
was accomplished by the use of a transgenic Tie2-Cre mouse
line that expresses Cre in endothelial cells of the embryo
(Kisanuki et al., 2001). This endothelial specific knockout of
ephrinB2 leads to angiogenic remodeling and cardiac defects
that are indistinguishable from those of the conventional
ephrinB2 knockout (Wang et al., 1998). These data
demonstrate that ephrinB2 is absolutely required in the
endothelial and endocardial cells of the developing mouse
embryo for proper cardiovascular development of both arteries
and veins. In all cases examined, ephrinB2 expression in
adjacent mesenchymal tissue was not sufficient to compensate
for the loss of endothelial expression in neighboring vessels.
MATERIALS AND METHODS
Generation of a floxed ephrinB2 allele
Genomic clones for the ephrinB2 locus were previously isolated
(Wang et al., 1998). A double-stranded oligonucleotide containing the
34 bp loxP site sequence and a 3 ¢ HindIII restriction site was inserted
into an EagI restriction site at position –45 bp in the 5 ¢ UTR of an
ephrinB2 genomic clone that included the first coding exon. From
this modified clone an EagI-EcoRI restriction fragment, which
encompassed the sequence from the loxP site through the end of
coding exon I, was ligated to a 2.8 kb XbaI-EagI genomic fragment
used as the left targeting arm. A 100 bp EcoRI-XbaI genomic
fragment starting at the end of exon I was cloned downstream of the
left targeting arm, thereby restoring the complete genomic sequence
of this locus. For construction of the right targeting arm, a 5.6 kb XbaI-
Asp718 genomic fragment starting 100 bp downstream of first coding
exon was cloned in multiple steps downstream of a loxP site-flanked
PGK-neomycin gene (Floxed PGKneo, a generous gift from J. Yoon
and B. Wold) derived from pPNT (Tybulewicz et al., 1991). This
PGKneo and right arm fragment was then joined to the left arm
construct. The resulting targeting construct thus contained 3 loxP sites
(Fig. 1A, ‘Targeting vector’ triangles). Cre recombinase mediated
deletion between the first and second sites results in loss of the
ephrinB2 first exon coding region, while deletion between the second
and third loxP sites results in deletion of the PGKneo cassette. 
Electroporation and selection of AB-1 ES cells (strain 129 SvJ)
were performed essentially as described (Ma et al., 1998), with the
exception that FIAU selection was omitted. ES cell targeting
efficiency via G418 selection was one out of 12 clones. Homologous
recombination of the targeted ephrinB2 locus in ES cells was
confirmed by HindIII restriction digest of genomic DNA and Southern
blotting. A 1 kb HindIII-XbaI genomic fragment upstream of the left
arm was used as a southern probe (Fig. 1A, ‘Probe A’) to distinguish
the wild-type (6 kb) or targeted (4 kb) ephrinB2 locus (Fig. 1B). 
To remove the Floxed PGKneo selection cassette, we used transient
expression of Cre recombinase. Uncut pBS185 plasmid (Invitrogen)
containing CMV-driven Cre recombinase expression was
electroporated into homologously recombinant ES cells, and the cells
were plated at high density. After 48 hours of growth, the cells were
trypsinized and replated at low density. Between 10 and 14 days of
growth, individual colonies were picked and replated into 96-well
plates. Southern blot analyses of genomic DNA isolated from plate
replicates identified ES clones that had undergone deletion of the
PGKneo cassette but retained an intact exon I (Fig. 1A, ‘Floxed
locus’; Fig. 1C, ‘Neo deleted’). Genomic DNA was cut with HindIII,
and a 1.2 kb EcoRI-HindIII genomic fragment was used as a Southern
probe (Fig. 1A, ‘Probe B’). Wild-type, exon 1-deleted and fully
deleted loci were indistinguishable using this Southern blot strategy,
as they all generate a band of approximately 6kb (Fig. 1C,
‘Wildtype’). Blastocyst injection of floxed ephrinB2 ES cells were
performed essentially as described (Ma et al., 1998). Germline
chimeras were crossed onto a pure C57/Bl6 background and all
subsequent breeding was done in a C57/Bl6 background.
Genotyping
PCR genotyping for the conditional ephrinB2 allele (floxed allele)
was performed with a 5 ¢ primer specific for the 5 ¢ loxP site insertion,
5¢ -AAGTTATAAGCTTCAACGCGTCC-3¢ (TF3), and a 3 ¢ primer
in the genomic region downstream of exon 1, 5 ¢ -GAGC-
CCCAGGTTCTAGAATAACTTCG-3¢ (RF1) (product size of 320
bp). Genotyping of the ephrinB2-lacZ allele was carried out with
the following lacZ-specific primer pair: 5¢ -CGCCCGTTGC-
ACCACAGATG-3¢ (UX-161) and 5 ¢ -CCAGCTGGCGTAA-
TAGCGAAG-3¢ (UX-160G) (product size of 370 bp). The Tie2-Cre
transgene was detected by allele specific primers, with a 5 ¢ primer
in the Tie2 promoter, 5¢ -GGGAAGTCGCAAAGTTGTGAGTT-3¢
(Tie2T5F1) and a 3¢ primer in the Cre gene, 5¢ -CTA-
GAGCCTGTTTTGCACGTTC-3¢ (Cre2) (product size of 490 bp).
The wild-type ephrinB2 locus was detected with a 5 ¢ primer
that includes sequence flanking the inserted 5 ¢ loxP site, and a 3¢
primer downstream of the first exon, 5¢ -GCTGCCCGCGGCCGG-
TCCCAACG-3 ¢ (BrgF1) and 5 ¢ -CCGTTAGTGGCAACGTCCTCC-
GTCCTCG-3 ¢ (HL-I-R2h) (product size of 580bp). Conditional
knockout mice were identified by the presence of loxP-allele specific,
lacZ allele specific and Tie2-Cre specific PCR products. Homozygous
ephrinB2-lacZ embryos were identified by the presence of lacZ-
specific PCR products and the absence of wild-type ephrinB2-specific
PCR products (in duplicate). Homozygous ephrinB2-loxP mice were
identified by the presence of loxP-allele specific PCR products and
the absence of wild-type ephrinB2-specific PCR products. In all
embryos, a small amount of tissue was collected from the tail region
for genomic DNA isolation and genotyping. To demonstrate deletion
of ephrinB2-loxP exon I in vivo, the following primers were used
to distinguish intact (636 bp) and deleted (309 bp) ephrinB2-loxP
alleles: 5¢ -CGGCCGGTCCATAACTTCGTATAGCA-3 ¢ (HLF1) and
5¢ -CCGTTAGTGGCAACGTCCTCCGTCCTCG-3 ¢ (HL-I-R2h).
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To generate conditionally deleted ephrinB2 embryos, we first
generated mice heterozygous for both the ephrinB2-lacZ allele and
the Tie2-Cre transgene (ephrinB2lacZ/+;Tie2-Cre+). These mice were
then crossed to ephrinB2-loxP (ephrinB2loxP/+) heterozygous (or
ephrinB2loxP/loxP homozygous) mice. EphrinB2 conventional
knockouts were generated by intercross of ephrinB2lacZ/+
heterozygotes (Wang et al., 1998). For vascular-specific Cre
Recombinase expression, we used the Tie2-Cre transgenic mouse
(Kisanuki et al., 2001). The Tie2-Cre expression pattern was examined
by crossing Tie2-Cre mice to the R26R Rosa lacZ reporter mice
(Soriano, 1999). Embryos were collected at E8.25-E9.5 and processed
as described below by X-gal development or immunofluorescent
double-labeling.
lacZ and immunohistochemical staining 
To examine lacZ expression, mouse embryos were dissected between
E8.25 and E9.5, fixed in 0.25% glutaraldehyde/PBS for 5 minutes,
rinsed twice with PBS, and stained overnight at 37°C in X-Gal buffer
[1.3 mg/ml potassium ferrocyanide, 1 mg/ml potassium ferricyanide,
0.2% Triton X-100, 1 mM MgCl2 and 1 mg/ml X-Gal in phosphate-
buffered saline (PBS, pH 7.2)]. For antibody staining, embryos were
first fixed overnight in 4% paraformaldehyde/PBS at 4°C. For section
staining, embryos were embedded in 15% sucrose and 7.5% gelatin
in PBS, and 15 m m sections were collected on a cryostat. Whole-
mount staining procedures with anti-PECAM1 antibody (clone MEC
13.3, Pharmingen, 1:200 overnight at 4°C) and anti- b -galactosidase
antibody (3-prime 5-prime, 1:1000, overnight at 4°C) were essentially
as described (Wang et al., 1998). Either HRP-conjugated secondary
antibodies (Jackson, 1:200, overnight at 4°C) or secondary antibodies
conjugated to FITC or Alexa-568 (Jackson, 1:200, and Molecular
Probes 1:250, 1 hour at room temperature) were used for whole-mount
staining. For immunofluorescent detection on sections, secondary
Fig. 1. Generation of the Floxed ephrinB2 locus. (A) Restriction maps of the wild-type ephrinB2 locus, the targeting vector, the initial targeted
locus, floxed locus after neo deletion and targeted locus after complete deletion. The targeting vector contains loxP sites (arrowheads) flanking
the first coding exon (gray bar). It also contains a floxed PGK-neomycin (‘PGKneo’) selection cassette that was subsequently removed by
transient Cre expression to avoid disturbing normal ephrinB2 transcription (see C). (B) Confirmation of homologous recombination of the
targeting vector by Southern blotting. The ES cell genomic DNA has been digested with HindIII, and hybridized with Southern probe A (see
A). Wild-type (6 kb) and targeted (4 kb) loci differ by a HindIII site flanking the 5¢ loxP site (see A). (C) Identification of ES cells that have
undergone PGKneo cassette deletion (see A) after transient Cre recombinase expression. Genomic DNA was digested with HindIII, and
hybridized with southern probe B (see A). ‘Neo deleted’ indicates loss of PGKneo cassette with retention of the first exon. Deletion of the
entire region or deletion of the floxed exon are not distinguishable from wild type in this Southern blot. (D) Confirmation of ephrinB2 exon 1
deletion in mice. Progeny of an ephrinB2loxP/+ X CMV-Cre cross show intact (long) or deleted (short) PCR products with primers specific for
the loxP allele.
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antibodies conjugated to FITC or Alexa-568 (Jackson, 1:200, and
Molecular Probes 1:250) were applied for 1 hour at room temperature.
For whole-mount immunofluorescent staining, embryos were cleared
in Vectorshield (Molecular Probes) for 20 minutes subsequent to the
final antibody wash, then mounted on a slide whose coverslip was
elevated by a bridge of two coverslips on each side. This enabled us
to avoid crushing the embryos. All confocal microscopy was carried
out on a Leica SP confocal (Leica). All brightfield images were
captured using an Axiocam CCD camera (Zeiss).
In situ hybridization
In situ hybridization was carried out essentially as described (Wang
et al., 1998; Birren et al., 1993). E9 embryos were cryosectioned at
15 m m, and adjacent sections were hybridized with RNA probes
against the ephrinB2 EC domain (Wang et al., 1998) and Flk1 (Kdr –
Mouse Genome Informatics; a generous gift from T. Sato).
RESULTS
Generation of a conditional ephrinB2 allele
To study the role of ephrinB2 specifically in the vasculature,
we generated a loxP flanked (floxed) ephrinB2 allele. A
targeting construct was created with one loxP site inserted into
the 5 ¢ UTR at –45bp, and a second site inserted 100 bp
downstream of exon I as part of a loxP flanked neomycin
resistance cassette (floxed PGKneo, Fig. 1A, ‘PGKneo’). This
arrangement placed loxP sites flanking exon I, which encodes
the ephrinB2 signal peptide, followed by the neor cassette.
Homologous recombinant ES cells were identified by G418
selection and southern analysis (Fig. 1B, ‘loxP-neo/+’). The
floxed neo cassette was then deleted by transient Cre
expression in ES cells. ES cells with only the neo cassette
deleted, and an intact loxP-flanked exon I (Fig. 1A, ‘Floxed
locus’), were identified by Southern analysis (Fig. 1C), and
used to generate chimeric mice. Subsequent intercrossing of F1
ephrinB2loxP/+ mice generated homozygous ephrinB2loxP/loxP
mice at expected Mendelian ratios. No obvious detriment to
the development and reproductive capacity of the mice
carrying two floxed alleles was observed. This suggests that the
genomic alteration introduced had no measurable effect on
ephrinB2 expression or function. 
To verify that the floxed ephrinB2 allele was able to undergo
Cre-mediated deletion, ephrinB2loxP/+ mice were crossed to a
CMV-Cre mouse, in which Cre is expressed in all cells of the
early embryo (Zinyk et al., 1998). Embryos that inherited both
the ephrinB2loxP allele and the CMV-Cre transgene show
deletion of the loxP allele by PCR analysis (Fig. 1D, right
panel, lower band, ‘deleted’). Embryos that inherited the
ephrinB2loxP allele but no Cre transgene showed no deletion
(Fig. 1D, left panel, upper band, ‘intact’). Sequencing of these
PCR products confirmed the deletion event (data not shown).
Deletion of ephrinB2 exon I by Cre recombinase removes the
signal peptide, creating a null allele similar in structure to the
original conventional ephrinB2 knockout allele (Wang et al.,
1998), but with no lacZ marker included.
Embryonic endothelial-specific Cre expression
To knock out ephrinB2 specifically in endothelial cells, we
used an endothelial-specific Cre-expressing transgenic mouse
line, Tie2-Cre (Kisanuki et al., 2001). Tie2, a pan-endothelial
receptor tyrosine kinase, is expressed from the earliest
timepoints of vascular development (Dumont et al., 1995;
Dumont et al., 1992). The Tie2 promoter/enhancer is well
characterized and has been shown to drive specifically
transcription in the majority of embryonic endothelial cells
(Schlaeger et al., 1995; Schlaeger et al., 1997).
ephrinB2 expression in the vasculature is first seen around
E8.25, immediately after the formation of the primary vascular
plexus (Wang et al., 1998). Homozygous ephrinB2lacZ/lacZ
mutants first exhibit cardiovascular defects around E9 (Wang
et al., 1998). These two timepoints define the interval during
which ephrinB2 function is first required in the vasculature. To
verify that the Tie2-Cre transgene is expressed during this
interval, we crossed Tie2-Cre+ mice to the Rosa26 reporter
(R26R) strain (Soriano, 1999). In the R26R reporter mice, a
floxed transcriptional/translational stop cassette (floxed STOP)
(Lakso et al., 1992) is present between the ubiquitously
expressing Rosa26 promoter and the lacZ gene. Any cell
expressing Cre will excise the floxed STOP, allowing lacZ
expression in that cell and all its progeny (Nagy, 2000). Using
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Fig. 2. Tie2-Cre activity in early embryogenesis is restricted to the
vasculature. (A-E) Widespread vascular activity of Tie2-Cre in the
progeny of a Tie2-Cre X R26R lacZ reporter cross at E8.25, revealed
by X-gal staining (blue color). (A) The highly vascularized yolk sac
(YS) shows intense Tie2-Cre activity. The primitive vasculature
throughout the embryo proper (arrowheads) also shows Tie2-Cre
activity. (B) Close-up photograph of intersomitic sprouts (arrows)
from the dorsal aorta (DA) of a similar embryo to (A) shows Tie2-
Cre activity in vessels undergoing angiogenic sprouting. (C-E)
Sections of littermates of A, showing Tie2-Cre activity in vessels
(arrowheads) of the head (C), hindbrain (D) and trunk (E). The
endocardial lining of the heart is also positive (E, arrows), as
expected (Kisanuki et al., 2000). Sections were counterstained with
Hematoxylin.
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this reporter line, we confirmed that Tie2-Cre is active
throughout the vasculature as early as E8.25 (Fig. 2). At this
stage, the yolk sac, a highly vascularized extra-embryonic
tissue, shows widespread Tie2-Cre activity (Fig. 2A ‘YS’). The
primitive vasculature of the embryo proper also shows Tie2-
Cre activity (Fig. 2A, arrowheads) throughout the vessels of
the head, heart region and trunk (Fig. 2C-E, respectively,
arrowheads). The endothelial lining of the heart, the
endocardium, is also positive, as expected (Fig. 2E, arrows)
(Kisanuki et al., 2001; Schlaeger et al., 1997). As ephrinB2
activity is thought to play a role in angiogenic sprouting
(Adams et al., 1999), we wanted to confirm that Tie2-Cre was
active in endothelial sprouts. Intersomitic vessels derived from
vascular sprouts of the dorsal aorta showed clear Tie2-Cre
activity (Fig. 2B, arrows, ‘DA’). Thus, Tie2-Cre is specifically
expressed in the endothelium, including angiogenic sprouts,
from a timepoint early enough to delete ephrinB2 when its
angiogenic function is first required (Adams et al., 1999; Wang
et al., 1998).
Vascular-specific deletion of ephrinB2 results in
growth arrest
In order to knock out ephrinB2 in the vasculature, we generated
mice heterozygous for both the conventional, lacZ-marked
ephrinB2 allele (Wang et al., 1998) and the Tie2-Cre transgene
(ephrinB2lacZ/+;Tie2-Cre+), and crossed them to ephrinB2loxP/+
(or ephrinB2loxP/loxP) mice. We collected embryos from this
cross at E9.5 and visualized the vasculature by whole-mount
antibody staining for PECAM1, a pan-endothelial marker
(Fig. 3). We observed a dramatic underdevelopment of
ephrinB2lacZ/loxP;Tie2-Cre+ embryos (Fig. 3C) compared
with wild-type littermates (Fig. 3A):
they were smaller and appeared
developmentally less advanced. Their
hearts were swollen, but were still
beating. Blood was occasionally seen
flowing through the aortic arches,
anterior cardinal veins (ACVs) and
dorsal aorta. The vasculature of
conditional knockouts was disorganized
and less intricately developed than that
of wild-type littermates, or littermates
that lack the Tie2-Cre transgene or one
of the targeted ephrinB2 alleles (Fig. 3D-
F). A conventional ephrinB2 mutant was
collected and stained side-by-side with
this litter for comparison (Fig. 3B). The vascular-specific
knockout (ephrinB2 lacZ/loxP;Tie2-Cre+) embryos appeared
similar to the conventional ephrinB2lacZ/lacZ mutants in their
reduced size, underdevelopment and vascular disorganization
(compare Fig. 3C with 3B). Conditional and conventional
knockout embryos were recovered at expected Mendelian
ratios at E9.5 (1 in 3.9 and 1 in 3.8 respectively, n=113 and
n=42). 100% of conditional mutants recovered at this stage
show growth arrest and vascular defects of the yolk sac,
embryo proper and heart (n=29).
EphrinB2 is required in endothelial cells for proper
peripheral angiogenesis
Yolk sac
A prominent site of angiogenesis in the early embryo is the
yolk sac, where a primitive vascular plexus of small diameter
capillaries is assembled by E8.5. This plexus rapidly remodels
into a complex, hierarchically branched network. In the yolk
sac, ephrinB2 expression is restricted to the endothelium of the
arteries (Wang et al., 1998) and is required for angiogenic
remodeling of the primary yolk sac plexus (Adams et al., 1999;
Wang et al., 1998). In situ hybridization of sectioned yolk sac
from E9 embryos with RNA probes to ephrinB2 and Flk1
confirmed that expression of ephrinB2 was restricted to the
endothelial, Flk1 positive cells (compare Fig. 4A with D). As
expected, therefore, in both the conditional and conventional
knockouts, ephrinB2 expression is absent from the yolk sac
(Fig. 4B,C versus A). 
The restriction of ephrinB2 expression in yolk sac to the
endothelium suggested that the phenotype of the endothelial
specific knockout in this tissue should be identical to that seen
Fig. 3. Gross morphology of conditional
ephrinB2 knockout embryos and littermates.
Comparison of embryos from an
ephrinB2lacZ/+;Tie2-Cre+ X ephrinB2loxP/+
cross (A,C-F), and from an ephrinB2lacZ/+
intercross (B) by anti-PECAM1 staining at
E9.5. The conditional ephrinB2 knockout
embryo (C) is growth retarded compared
with its wild-type littermates (A) and
littermates that lack either the Tie2-Cre
allele or one of the targeted ephrinB2 alleles
(D-F). An ephrinB2-lacZ homozygous
embryo (B) shows developmental arrest
similar to the conditional knockout embryo
(compare with C).
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in the conventional ephrinB2 knockout. Examination of the
yolk sac vasculature of endothelial-specific ephrinB2 knockout
embryos (ephrinB2lacZ/loxP; Tie2-Cre+) at E9.5 confirmed this,
revealing that the failure of arterial and venous angiogenesis
identical to that seen in the ephrinB2lacZ/lacZ homozygous
embryos (Fig. 4I versus 4H, and data not shown). The yolk sac
vasculature in the conditional knockout was a homogeneous
capillary bed, suggesting an arrest in development of arteries
and veins at the primary plexus stage. This is in stark contrast
to the yolk sac vasculature of littermates, where extensive
remodeling of vessels is seen by this age (compare Fig. 4G
with I).
EphrinB2 expressed in arteries is required for
remodeling of the anterior cardinal vein
The anterior cardinal veins are the main vessels that transport
blood from the head back through the sinus venosus to the
heart. These lateral vessels appear around E8.5, after the
formation of the dorsal aorta. Each ACV arises initially from
the fusion of multiple small vessels present in the lateral
mesenchyme of the hindbrain and head (Coffin and Poole,
1988). The early, small diameter vessels that will give rise to
the ACVs express EphB4 receptor (Gerety et al., 1999).
EphrinB2 is expressed extensively in the hindbrain
mesenchyme surrounding the developing ACV, as well as in
neighboring neuroepithelium (Fig. 5A-C, red channel, black
and white arrowheads, respectively) (Wang et al., 1998). Both
ephrinB2lacZ and Ephb4lacZ homozygous embryos show a
failure of ACV assembly, resulting in a plexus of disorganized
small-diameter vessels (Fig. 5N) (Adams et al., 1999; Gerety
et al., 1999). This angiogenic remodeling defect, in a place
where no arteriovenous (AV) interface is apparent at E9.5,
suggested that ephrinB2 from perivascular mesenchymal cells
might signal to EphB4-expressing vessels (Gerety et al., 1999).
Double-labeling of E9.5 embryos from a Tie2-Cre X R26R
lacZ reporter cross with anti-PECAM1 and anti-b -Gal
confirmed that Tie2-Cre is active only in the endothelium of
the hindbrain (Fig. 5D-F, green and red channels, respectively,
arrows). We confirmed vessel-specific deletion by in situ
hybridization on conventionally and conditionally knocked-out
embryos and littermates (Fig. 5G-L). Comparison of ephrinB2
probe and Flk1 probe staining shows that ephrinB2 was
selectively lost in the endothelium (Fig. 5I,L versus 5G,J,
arrows), and was still present in the non-vascular tissues (Fig.
5G versus I, arrowheads) of conditional knockout embryos.
Flk1 in situ hybridization signals confirmed the presence of
endothelial cells in these samples (Fig. 5J-L).
We anticipated that the endothelial specific knockout of
ephrinB2 might result in a rescue by mesenchymal ephrinB2
of the ACV phenotype seen conventional ephrinB2lacZ/lacZ
homozygous mutants. To our surprise, ephrinB2lacZ/loxP;Tie2-
Cre+ embryos at E9.5 show a failure of ACV assembly and
remodeling (compare Fig. 5M with O, arrows). This defect
was indistinguishable from that seen in ephrinB2lacZ/lacZ
homozygotes (compare Fig. 5N with O, arrows). To understand
how the loss of endothelial ephrinB2 could affect the
development of venous vessels apparently not in direct contact
with ephrinB2-expressing arteries, we collected ephrinB2lacZ/+
embryos at the 12-13 somite stage (E8.5), a timepoint at which
the ACV is in the process of forming, and 24 hours before the
mutant phenotype is clearly visible in the ACV. The embryos
were stained with anti-PECAM1, and anti- b -gal to detect the
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Fig. 4. Yolk sac angiogenesis is
defective in conditional ephrinB2
knockout embryos. (A-F) Restriction
of ephrinB2 mRNA expression to
endothelial cells of the E9 yolk sac is
revealed by in situ hybridization with
ephrinB2 (A-C) and Flk1 (an
endothelial-specific marker, D-F)
RNA probes on sections of
ephrinB2lacZ/+ control (A,D)
ephrinB2lacZ/lacZ (B,E) and conditional
ephrinB2 knockout (C,F) yolk sacs at
E9. EphrinB2 mRNA in controls is
expressed in Flk1-positive endothelial
cells (A versus D), and is lost in both
conventional (B) and conditional (C)
ephrinB2 mutants. (G-I) Identical
defects in yolk sac vessel remodeling
are seen in ephrinB2lacZ/lacZ (H) and
conditional ephrinB2 (I) knockout
embryos compared with
ephrinB2lacZ/+ controls (G) are
revealed by whole-mount anti-
PECAM1 staining of E9.5 yolk sacs.
The large (arrow) and small
(arrowheads) branches in control yolk
sacs (G) are instead a plexus of
equally sized capillaries (arrowheads)
in both mutants (H,I).
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ephrinB2-lacZ expression. As expected (Wang et al., 1998), the
dorsal aorta was positive for b -gal (Fig. 5P-R, red channel,
arrows), as was the surrounding mesenchyme (Fig. 5P-R, red
channel, black arrowheads). We observed numerous small
branches emanating from the dorsal aorta (Fig. 5P-R, white
arrowheads), extending to the forming ACV (Fig. 5P-R,
outlined by broken white lines). This reveals that there is a
transient continuity between the developing ACV network and
the fully formed dorsal aorta at early stages, and that most these
vessels appear to be pruned by E9.5. This transient contact may
represent the locus at which arterial ephrinB2 function is
required for proper ACV morphogenesis. Thus, these data
suggest that ephrinB2 expressed in arterial endothelial cells is
required for proper angiogenesis of veins.
Endothelial ephrinB2 is required for angiogenesis of
arteries in the head
Vascularization of the head results in a characteristic
hierarchical branching pattern of large to small vessels,
including morphogenesis of the internal carotid artery (ICA)
(Coffin and Poole, 1988). In ephrinB2lacZ/lacZ homozygous
mutant embryos, this network does not develop properly,
resulting in a disorganized, often fused network of capillaries
(Fig. 6N) (Adams et al., 1999; Wang et al., 1998). EphrinB2
is expressed in arterial endothelial cells of the head (Fig. 6A,B,
red channel, arrows), as well as extensively in the mesenchyme
and neuroepithelium of the developing brain (Fig. 6A,B, red
channel, black and white arrowheads respectively) (Wang
et al., 1998). Previous studies have indicted that ephrinB2
Fig. 5. Defective remodeling of the anterior
cardinal vein (ACV) of conditionally deleted
ephrinB2 embryos. (A-C) EphrinB2 expression is
widespread in the hindbrain. EphrinB2lacZ/+ mice at
E9.5 were sectioned and stained for PECAM-1 (A
and C, green channel) and b -gal (A and B, red
channel). A merged image in A shows ephrinB2
expression in both arterial endothelium (yellow,
arrows) and non-endothelial mesenchyme (red
channel, black arrowheads) and neuroepithelium
(red channel, white arrowheads). (D-F) Tie2-Cre
activity is restricted to endothelial cells of the
hindbrain. Embryos from a Tie2-Cre X Rosa-lacZ
reporter cross at E9.5, sectioned and stained for
PECAM-1 (D and F, green channel) and b -gal (D
and E, red channel) show complete overlap
(arrows). A merged image is shown in (D). (G-L)
EphrinB2 mRNA expression is lost specifically in
the hindbrain vasculature of conditional knockout
embryos. Sections through ephrinB2lacZ/+ (G,J),
ephrinB2lacZ/lacZ (H,K) and ephrinB2lacZ/loxP;Tie2-
Cre+ (conditional knockout, I,L) hindbrain regions
were hybridized with RNA in situ probes to
ephrinB2 (G-I) and Flk1 (J-L), and show loss of
ephrinB2 in vessels of conditional knockout
embryos (compare G and J with I and L, arrows).
EphrinB2 mRNA is completely absent in the
ephrinB2lacZ/lacZ conventional knockout (H) but
remains in the mesenchyme (white arrowheads) and
neuroepithelium (black arrowheads) of conditional
knockout embryos (compare G versus I). (M-O)
Whole-mount PECAM-1 staining shows a failure
of assembly of the ACV in conditional knockout
embryos compared with ephrinB2lacZ/+ controls
(compare O with M, arrows). EphrinB2lacZ/lacZ
embryos show an identical vascular phenotype
(compare O with N). Image in O is a close-up of
embryo in Fig. 3C. (P-R) Vascular sprouts connect
the ACV to the dorsal aorta at E8.5. Whole-mount
staining for PECAM1 (P,R, green channel) and b -
gal (P,Q, red channel) of ephrinB2lacZ/+ mice show
multiple vascular branches (P and R, white
arrowheads) interconnecting the ACV primordium
(P-R, outlined by broken white lines) and the
ephrinB2 expressing dorsal aorta (arrows). A
merged image in (P) shows mesenchymal ephrinB2
expression (red, black arrowheads) surrounding the
immature ACV plexus (green channel, outlined by
broken white lines).
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function is essential for angiogenesis of vessels
in the head, but were unable to distinguish
an autonomous requirement for ephrinB2 in
the blood vessels, from a requirement in
the neighboring head mesenchyme or
neuroepithelium (Adams et al., 1999; Wang et al.,
1998).
To examine Tie2-Cre activity in the head, we
collected embryos at E9.5 from a Tie2-Cre X
R26R lacZ reporter cross. Double-labeling with
anti-PECAM1 and anti-b -gal (Fig. 6D-F, green
and red channels, respectively) confirmed that
lacZ expression was only activated in the
endothelium of the head (Fig. 6A versus 6D,
arrows). To confirm that ephrinB2 expression
was selectively lost in the vessels of
ephrinB2lacZ/loxP;Tie2-Cre+ mice, in situ
hybridization with ephrinB2 and Flk1 RNA
probes was performed on conventionally and
conditionally knocked-out embryos and
littermates. Comparison of ephrinB2 probe and
Flk1 probe staining indicated that ephrinB2 was
selectively lost in the vasculature (Fig. 6G-I
versus 6J-L, arrows), and was still present in the
non-vascular sites (Fig. 6G,I, arrowheads), of
conditional knockout embryos. As expected, no
ephrinB2 signal was present in ephrinB2lacZ/lacZ
embryos (Fig. 6H). Flk1 in situ hybridization
signals in all samples confirmed that the loss of
vascular ephrinB2 signals in mutant embryos was
not due to a loss of endothelial cells in these
samples (Fig. 6J-L, arrows).
In ephrinB2lacZ/loxP;Tie2-Cre+ embryos the
head vasculature fails to assemble correctly (Fig.
6M versus 6O). The initial head plexus forms, but
subsequently remains in a primitive state, a
disorganized network of dilated capillaries. The
ephrinB2lacZ/lacZ homozygous mutant embryos
exhibit an identical phenotype (compare Fig. 6N
versus 6O). Thus, in the conditional knockout of
ephrinB2, the absence of endothelial ephrinB2
expression results in defective remodeling of the
ICA, as well as the branches of the ACV, despite
high mesenchymal and neuroepithelial ephrinB2
expression at this stage (Fig. 6A,B, red channel,
arrowheads). These data indicate that endothelial
ephrinB2 is required autonomously in arteries for
proper arterial angiogenesis.
To determine whether the angiogenic
phenotype of the conditional mutant reflects
aberrant perivascular smooth muscle cell (SMC)
recruitment or differentiation, we stained
embryos at E9.5 with antibody to a smooth
muscle actin (a SMA). At this stage, however,
there was not yet any a SMA expression in wild-
type embryos in the smaller peripheral vessels of
the ICA where phenotypic defects are observed
in the mutant (data not shown). Therefore,
it seems unlikely that a defect in SMC
differentiation can account for the defective
angiogenesis observed in the mutants. However,
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Fig. 6. Defective angiogenesis in the heads of conditionally deleted ephrinB2
embryos. (A-C) EphrinB2 expression is widespread in the head. EphrinB2lacZ/+ mice
at E9.5 were sectioned and stained for PECAM1 (A,C, green channel) and b -gal
(A,B, red channel). A merged image in A shows ephrinB2 expression in both
endothelial (yellow) and non-endothelial (red) mesenchymal (black arrowheads) and
neuroepithelial (white arrowheads) tissues; ICA, internal carotid artery. (D-F) Tie2-
Cre activity in the head is restricted to endothelial cells. Embryos from a Tie2-Cre X
Rosa-lacZ reporter cross at E9.5, sectioned and stained for PECAM-1 (D,F, green
channel) and b -gal (D,E, red channel), show complete overlap. A merged image is
shown in D. (G-L) EphrinB2 mRNA expression is lost specifically in the vessels of
conditional knockout embryos. Sections through ephrinB2lacZ/+ (G,J),
ephrinB2lacZ/lacZ (H,K) and ephrinB2lacZ/loxP;Tie2-Cre+ (conditional knockout, I,L)
were hybridized with RNA in situ probes to ephrinB2 (G-I) and Flk1 (J-L), and
show loss of ephrinB2 in vessels of conditional knockout embryos (compare G and J
with I and L, arrows). ephrinB2 mRNA is completely lost in the ephrinB2lacZ/lacZ
conventional knockout (H), but remains in the mesenchyme (white arrowheads) and
neuroepithelium (black arrowheads) of conditional knockout embryos (compare G
with I). (M-O) Whole-mount PECAM1 staining shows arrested vascular remodeling
in the heads of conditional ephrinB2 knockouts compared with littermate controls
(compare O with M). ephrinB2lacZ/lacZ heads show an identical vascular phenotype
(compare O with N). Images in M,O are close-ups of embryos in Fig. 3F,C,
respectively.
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it is possible that earlier markers of undifferentiated pericytes
might reveal such a defect.
Endothelial ephrinB2 is required for angiogenesis of
intersomitic vessels
The embryonic trunk is initially vascularized
by a series of intersomitic vessels (ISVs) that
arise from branches of the dorsal aorta
(DA) and posterior cardinal veins. These
vessels grow between adjacent somites to
form a simple interconnected network
dorsally around E8.75. Through extensive
angiogenesis, this primitive structure
elaborates an intricate network of small
capillaries (Fig. 7M), some of which
eventually invade the developing neural tube
and flanking somites (Drake and Fleming,
2000; Coffin and Poole, 1988).
EphrinB2 is expressed in the arterial
branches of the intersomitic vessels (Fig. 7A-
C, red channel, arrows) (Gerety et al., 1999)
as well as in the caudal region of adjacent
developing somites (Fig. 7A-C, red channel,
arrowheads) (Adams et al., 1999; Gerety et al.,
1999; Durbin et al., 1998; Wang et al., 1998;
Wang and Anderson, 1997). ephrinB2
homozygous mutants fail to undergo
angiogenic remodeling of the intersomitic
vasculature (Fig. 7N) (Adams et al., 1999;
Gerety et al., 1999). A similar phenotype is
seen in mutants that lack EphB4, which is
specifically expressed in ISVs and not in
somitic mesenchyme (Gerety et al., 1999).
Somitic ephrinB2 has also been implicated in
ISV guidance in mouse and Xenopus
(Helbling et al., 2000; Adams et al., 1999),
although the penetrance of this phenotype
appears variable in mice (Gerety et al., 1999).
To confirm that Cre activity is restricted to
ISVs in the trunk, we examined embryos from
a Tie2-Cre X R26R lacZ reporter intercross.
Double-staining of such embryos for
PECAM1 and b -gal confirmed that the lacZ
reporter was specifically activated in the
vessels (Fig. 7D-F, arrows), and not in the
somites or other surrounding tissues (compare
Fig. 7A with 7D). These data suggested
that ephrinB2 expression should be
selectively eliminated in the ISVs of
ephrinB2lacZ/loxP;Tie2-Cre+ mice. To confirm
this, in situ hybridization with ephrinB2 and
Flk1 RNA probes was performed. Consistent
with the Tie2-Cre X reporter data (Fig. 7D-F),
these experiments indicated that in the
conditional knockout, ephrinB2 is selectively
lost in the vasculature (Fig. 7G-I versus J-L,
insets, arrows, ‘V’), but is still present in
somites (Fig. 7G-I, arrowheads, and insets,
‘S’). Endothelial cells are still present,
however, as revealed by Flk1 probe signals in
all genotypes (Fig. 7J-L, arrows, and insets,
‘V’). Complete loss of ephrinB2 in situ signal in the ephrinB2
conventional knockout confirmed the specificity of the
riboprobes used (Fig. 7H).
Endothelial-specific ephrinB2 knockout embryos
(ephrinB2lacZ/loxP;Tie2-Cre+) show an arrest in intersomitic
Fig. 7. Angiogenic arrest of the intersomitic vasculature in conditional ephrinB2
knockout embryos. (A-C) EphrinB2 expression is present in vascular and non-vascular
trunk tissues. EphrinB2lacZ/+ mice at E8.5 were stained in whole-mount for PECAM1
(A,C, green channel) and b -gal (A,B, red channel). The dorsal aorta and its intersomitic
sprouts (A-C, arrows) express ephrinB2-lacZ (red channel), as does the caudal half of
each somite (A,B arrowheads). (D-F) Tie2-Cre activity is restricted to endothelial cells
in the trunk. Whole-mount staining for PECAM1 (D,F, green channel) and b -gal (D,E,
red channel) of E8.5 progeny of a Tie2-Cre X R26R lacZ reporter cross shows that b -gal
expression, reflecting Tie2-Cre activity (E), is restricted to endothelial cells of the dorsal
aorta and intersomitic vessels (D-F, arrows), as seen in merged image (D, yellow).
(G-L) EphrinB2 mRNA is still expressed in the somites of the conditional ephrinB2
knockout, as revealed by in situ hybridization with ephrinB2 (G-I) and Flk1 (J-L) RNA
probes in E9 ephrinB2lacZ/+ control (G,J), ephrinB2lacZ/lacZ mutant (H,K) and
conditional ephrinB2 knockout (I,L) embryos. Somite expression of ephrinB2 in caudal
half of somites (G-I, arrowheads) is completely lost in conventional knockout (H) but is
still present in the vessel-specific knockout (I), compared with control embryos (G).
Insets in G-L confirm ephrinB2 expression in ISVs of ephrinB2lacZ/+ control embryos
(G versus J, arrows), and its absence from these vessels in conventional (H versus K,
arrows) and conditional mutants (I versus L, arrows); S, somite; V, vessel.
(M-O) Absence of intersomitic vessel remodeling at E9.5 is revealed by whole-mount
staining for PECAM1 in control ephrinB2lacZ/+ (M), ephrinB2lacZ/lacZ (N) and
conditional knockout (O) embryos. The ISV network is fused dorsally in both
conventional (N) and conditional (O) ephrinB2 mutants, when compared with the
elaborated network in control embryos (compare N and O with M). ISV guidance
appears normal in both conventional and conditional mutant embryos (M-O,
arrowheads). Images in M,N are close-ups of embryos in Fig. 3F,B, respectively. 
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vessel angiogenesis at the primary plexus stage (Fig. 7O,
compare with 7M). The vessels appear fused dorsally with little
or no branching. This phenotype is identical to that of the
ephrinB2lacZ/lacZ mice (compare Fig. 7N with 7O) (Gerety et
al., 1999). These data indicate that ephrinB2 is required in the
intersomitic arteries for proper angiogenesis to occur. Thus,
remodeling of ISVs requires ephrinB2-EphB4-mediated
interactions between ISVs. Somite-derived ephrinB2 signal is
apparently not sufficient to compensate for the requirement for
ephrinB2 in these vessels. 
We did not observe aberrant branching of ISVs into somitic
mesenchyme in either our conventional or conditional
ephrinB2 knockouts (Fig. 7N,O, arrowheads). This is in
contrast to the phenotype described by Adams
et al., in their conventional ephrinB2 knockout
(Adams et al., 1999), as well as in a study
employing mis-expression of dominant-negative
Ephb4 alleles in Xenopus (Helbling et al., 2000),
both of which describe aberrant ISV branches into
adjacent somites. The difference in the penetrance
of the ISV branching phenotype between the two
conventional ephrinB2 mutations may reflect
differences in genetic background (Gupta et al.,
2001; Rohan et al., 2000). Consequently, we were
unable to determine whether arterial ephrinB2
expression is required for proper intersomitic
guidance of the ISVs. The question of whether
ephrinB2 in somitic mesenchyme plays a role in
guidance of ISVs will require a conditional
knockout of the gene specifically in that tissue, on
a genetic background that allows the penetrance of
that phenotype.
Endocardial ephrinB2 is required for heart
development
The endothelial lining of the early embryonic
heart, the endocardium, is similar in many respects
to the rest of the vasculature, in terms of gene
expression, and cell behavior (reviewed by Gale
and Yancopoulos, 1999; Brutsaert et al., 1998;
Dumont et al., 1992; Dumont et al., 1995).
Subsequent interactions with its specialized tissue
environment leads to morphological changes,
including heart looping and myocardial
trabeculation, the formation of endothelial-cell
lined projections from the supporting myocardium
(Fishman and Chien, 1997). In the heart, ephrinB2
is expressed primarily in the endocardium (Fig.
8A-C, red channel, arrows) (Wang et al., 1998).
EphrinB2 is also weakly expressed in myocardium
or other support cells (Fig. 8A-C, red channel,
arrowheads) (Wang et al., 1998). The heart
phenotype in the conventional ephrinB2 knockout
is an arrest of development resulting in no looping
and little or no myocardial trabeculation, and
frequent abnormal swelling of the heart (Adams et
al., 1999; Gerety et al., 1999; Wang et al., 1998).
The Tie2-Cre deleter line we used excises in the
heart (Fig. 8D-F, red channel) (Kisanuki et al.,
2001), as early as E8.25 (Fig. 2E, arrows). No
Tie2-Cre activity was seen outside of the
endocardial lining (Fig. 8D-F, arrows, compare red and green
channels for b -gal and PECAM1, respectively). Specific loss
of ephrinB2 from the endocardium, and not from the
myocardium, of conditional knockout embryos was confirmed
by in situ hybridization (data not shown). In such
conditionally deleted embryos (ephrinB2lacZ/loxP;Tie2-Cre+),
we observed defective heart morphogenesis, including looping
defects, swelling (Fig. 8I versus 8G) and severely reduced
trabeculation (Fig. 8L versus J, arrowheads) compared with
littermate controls. We observed the same phenotype in
ephrinB2lacZ/lacZ homozygous embryos (Fig. 8H,K versus
8I,L) (Adams et al., 1999; Gerety et al., 1999; Wang et al.,
1998). Thus, endocardial ephrinB2 is essential for heart
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Fig. 8. Defective heart morphogenesis in both ephrinB2 conventional and
conditional mutant embryos. (A-C) EphrinB2 is primarily expressed in the
endocardial lining (arrows) of the heart, as revealed by sections of E9.5
ephrinB2lacZ/+ embryos stained for PECAM1 (A,C, green channel) and b -gal (A,B,
red channel). Some non-endocardial staining is seen (A-C, red channel not
overlapping with green, arrowheads). (D-F) In the heart, restriction of Tie2-Cre
activity to the endocardial lining is revealed by E9.5 sections of Tie2-Cre X R26R
lacZ reporter cross embryos double-labeled for PECAM1 (D,F, green channel) and
b -gal (D,E, red channel). A merged image (D) shows Tie2-Cre activity is found
only in the PECAM1-positive endocardial lining (arrows). (G-I) EphrinB2
conventional and conditional embryos show swelling and defective looping of the
heart compared with control ephrinB2lacZ/+ embryos (compare H and I with G),
revealed by whole-mount anti-PECAM1 staining at E9.5. (J-L) PECAM1 stained
sections of hearts reveal little or no myocardial trabeculation (arrowheads) in both
the conditional and conventional mutants (compare L with K) compared with
control embryos (compare K and L with J, arrowheads) at E9.5.
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morphogenesis. We observe heart beat and circulating
erythrocytes in the aortic arches and dorsal aorta of some
conditional ephrinB2 mutant embryos with vascular defects,
suggesting that cardiac function is not completely lost at
stages when peripheral angiogenic defects are visible.
DISCUSSION
Previous work established that ephrinB2 is specifically
expressed in arteries and is required for embryonic
angiogenesis (Adams et al., 1999; Wang et al., 1998). However,
as ephrinB2 is expressed not only in endothelium, but also in
mesenchymal tissues surrounding sites of angiogenesis, these
studies could not distinguish between a vascular requirement
and a mesenchymal requirement for the ephrinB2 signal.
Understanding which tissues provide angiogenic ephrin signals
influences the way we think about angiogenesis and the
regulation of its morphogenetic processes (Yancopoulos et al.,
2000). By knocking out ephrinB2 specifically in the developing
vasculature, we have shown that endothelial and/or endocardial
ephrinB2 expression is absolutely required for embryonic
angiogenesis. The extensive mesenchymal expression of
ephrinB2 around sites of active angiogenesis is not sufficient
to compensate for the loss of endothelial ephrinB2.
The functional requirement for ephrinB2 is intrinsic
to the cardiovascular system
Our data demonstrate that ephrinB2 is required in arterial
endothelium for the remodeling of veins of the head, ACV and
yolk sac, most probably by signaling through EphB4 receptor
in these vessels. This ligand appears to be required cell-
autonomously in arteries as well, without which angiogenic
remodeling of the ICA and vitelline artery is disrupted in the
head and yolk sac, respectively. Although ephrinB2 is
expressed at high levels in the somites flanking the developing
ISVs, endothelial ephrinB2 is still required for the elaboration
of a fine capillary network from the primitive intersomitic
arteries and veins. These data, therefore, appear to reveal
instances of forward, reverse and bi-directional signaling
between arterial and venous vessels. Our results also
demonstrate that even at sites of high mesenchymal ephrinB2,
vascular expression is still absolutely essential, and argue that
mesenchymal ephrinB2 alone is unable to support
angiogenesis.
Our data do not exclude the possibility, however, that somitic
ephrinB2 contributes to ISV growth and guidance. Adams et
al., observe ISVs branching aberrantly into the somites in their
ephrinB2 knockout, suggesting that ephrinB2 in the somites
plays repulsive role, restricting the growth of ISVs to the
intersomitic space (Adams et al., 1999). Our ephrinB2
knockout mice do not show a similar aberrant branching
phenotype (Gerety et al., 1999). The reason for this difference
is not clear. Strain differences may account for this discrepancy
(Gupta et al., 2001; Rohan et al., 2000). Consistent with this,
Adams et al. find ephrinB2 heterozygous offspring at half the
expected proportions (Adams et al., 1999), while our ephrinB2
offspring are found at Mendelian ratios, suggestive of a
reduced penetrance of the ephrinB2 mutant phenotype. Forced
expression of ephrins or dominant-negative EphB4 receptor
throughout the developing Xenopus embryo has a similar effect
on ISV growth (Helbling et al., 2000). This ISV guidance
model fits well with the repulsive guidance role ascribed to
ephrinB2 signaling in neural crest migration and axon
pathfinding in and around somitic tissue (Krull et al., 1997;
Wang and Anderson, 1997). However, somite-specific deletion
of ephrinB2 will be required to confirm that it exerts this ISV
guidance function from non-vascular tissue.
Necessity versus sufficiency: does mesenchymal
ephrinB2 have a role in angiogenesis?
Our loss-of-function results provide evidence of the necessity
of endothelial ephrinB2 in angiogenesis, and indicate that
mesenchymal ephrinB2 is insufficient to compensate for its
loss from vessels. However, this does not address whether
mesenchymal ephrinB2 expression is also required for
angiogenesis. Given the extensive expression of ephrinB2 in
the mesenchyme surrounding vessels in the head, trunk
(Adams et al., 1999; Wang et al., 1998) and in smooth muscle
(Gale et al., 2001; Shin et al., 2001), it is possible that this
non-endothelial expression is required for angiogenesis in
parallel with its requirement in the endothelium. If so, then
the fact that the phenotypes of the conventional and
endothelial-specific ephrinB2 knockouts are identical argues
that such a parallel function for ephrinB2 in endothelial and
mesenchymal cells must be non-redundant. Alternatively, the
presence of ephrinB2 in the early embryonic mesenchyme
may be irrelevant to angiogenesis, but instead reflects other
potential roles, such as somite patterning (Durbin et al.,
1998), neural crest migration (Adams et al., 2001; Krull et al.,
1997; Wang and Anderson, 1997), hindbrain segmentation
(Xu et al., 1995; Xu et al., 1996) and axon guidance (Frisen
et al., 1998; Drescher et al., 1995). The direct test of a
mesenchymal requirement for ephrinB2 in angiogenesis
awaits the identification of mesenchymal promoter elements
with which to generate mesenchyme-specific Cre deleter
mice.
ACV remodeling requires artery to vein ephrin
signaling
It has been hypothesized that the failure of ACV primordium
to remodel into single-vessel structures in the ephrinB2 and
Ephb4 mutants was the result of a loss of ephrinB2 stimulation
from the adjacent mesenchyme (Adams et al., 1999; Gerety et
al., 1999). An important factor in that interpretation was the
lack of obvious AV interface between this venous structure
and any arterial ephrinB2-expressing vessels. Based on this,
we expected that in an endothelial-specific knockout of
ephrinB2, we would see rescue of the ACV phenotype.
Surprisingly, the ACV phenotype of our conditional knockout
is identical to that of the conventional ephrinB2 knockout
(Adams et al., 1999; Gerety et al., 1999). This suggests
that an arterial source of ephrinB2 is required for ACV
morphogenesis, such as the dorsal aorta. How could a
physically remote tissue send a signal that is by nature
membrane bound and requires cell-cell contact for
transmission? Further analysis revealed transient endothelial
continuity between the dorsal aorta and the developing ACV
plexus at developmentally relevant stages during the assembly
of these vessels. Based on the combination of conditional
knockout phenotypes and the dorsal aorta-ACV contacts
present in young embryos, we believe that the development of
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the ACV may require transient artery-vein interactions. This
suggests that ACV development proceeds in a fashion similar
to the rest of the vasculature, through AV interactions during
which some vessels undergo pruning. Alternately, defective
angiogenesis in the ACV might instead be due to insufficient
blood flow resulting from aberrant cardiac development and
function (see next section).
Heart morphogenesis requires endocardial ephrinB2
expression
During embryonic heart morphogenesis, essential interactions
take place between endocardial cells (Gory-Faure et al., 1999),
and between endocardial and myocardial cells (Meyer and
Birchmeier, 1995) in a reciprocal manner (Carmeliet et al.,
1996; Suri et al., 1996). These tissue relationships are essential
for the remodeling of the primitive heart tube to the looped,
highly trabeculated structure that emerges at E9.5 (Gale and
Yancopoulos, 1999). Ephrin/Eph signaling has been implicated
in these morphogenetic events both by expression and mutant
phenotypes (reviewed by Adams and Klein, 2000). Because
EphB4 is expressed in endocardial and not myocardial cells,
the failure of myocardial trabeculation in the Ephb4 knockout
demonstrates that Ephrin signals must be received by the
endocardium (Gerety et al., 1999). Establishing the required
source for the ephrinB2 signal is complicated again by the
presence of this ligand in both the endocardium and the
myocardium (Wang et al., 1998). Although the expression
levels in the myocardium are much lower than in the
endocardium, the possibility remained that the requisite Ephrin
signal originates in the myocardium. We now show that
endocardial ephrinB2 function is absolutely required for heart
morphogenesis, and is not compensated for by myocardial
ephrinB2. This indicates that ephrinB2-EphB4-mediated
signaling between endocardial cells is required for this
morphogenetic program to be executed.
The close temporal relationship between vascular and cardiac
phenotypes in knockouts of most genes encoding angiogenic
signaling molecules or their receptors (Gerety et al., 1999;
Gory-Faure et al., 1999; Asahara et al., 1998; Carmeliet et al.,
1996; Ferrara et al., 1996; Dickson et al., 1995; Sato et al., 1995;
Dumont et al., 1994) invariably complicates phenotypic
analysis and interpretation: a defect in peripheral angiogenesis
could be the result of defective cardiac development and
aberrant blood flow; conversely, defective heart development
could be due to an obstructed or disorganized vasculature. We
do observe heartbeat and blood flow in some conditional
ephrinB2 mutant embryos with vascular defects, arguing that
the defective peripheral angiogenesis in such mutants is not
simply due to a complete lack of blood flow. However, aberrant
hemodynamics could still contribute to the peripheral
angiogenic defects seen in mutant embryos. Resolution of this
issue awaits the development of appropriate Cre deleter
transgenic mouse lines to temporally bypass the early cardiac
requirement for ephrinB2 function, or alternatively
identification of endothelial- or endocardial-specific promoter
elements (Fishman, 1997), for loss-of-function or rescue
experiments, respectively.
EphrinB1 does not compensate for loss of
endothelial ephrinB2
EphrinB1 is co-expressed with ephrinB2 in arteries (Adams et
al., 1999), but cannot compensate for the loss of ephrinB2 in
a conventional knockout (Adams et al., 1999; Wang et al.,
1998). The perivascular expression of these ligands, however,
does not fully overlap (Wang and Anderson, 1997). Previously,
therefore, one could have argued that the failure of ephrinB1
to compensate for ephrinB2 in the conventional knockout
might reflect a requirement for ephrinB2 function in tissues
where ephrinB1 is not expressed. However, the present data
indicate that ephrinB1 cannot compensate for ephrinB2 within
the cardiovascular system. This failure may reflect crucial
differences in expression levels between the two ligands (Stein
et al., 1998), or alternatively structural differences that create
different functional properties. For example, ephrinB2 is the
only ligand that can bind efficiently to EphB4 (Sakano et al.,
1996; Brambilla et al., 1995). Although veins express other
EphB receptors that can interact with ephrinB1, only EphB4 is
essential for angiogenesis (Adams et al., 1999; Gerety et al.,
1999). Finally, differences in expression patterns within the
cardiovascular system could explain the inability of ephrinB1
to compensate for ephrinB2: although ephrinB2 is expressed
only in arterial vessels (Adams et al., 1999; Wang et al., 1998),
ephrinB1 is expressed in all vessels (Adams et al., 1999). The
arterial restriction of ephrinB2 may therefore be an important
aspect of its role in angiogenesis. Gene swapping experiments
should reveal whether differences in the expression or activity
of ephrinB1 and ephrinB2 account for their functional
distinction.
Reverse signaling by ephrinB2 in angiogenesis
The interpretation of the vascular defects in the original
ephrinB2 knockout was that reciprocal signaling between
arterial ephrinB2 and venous EphB4 is required for the
remodeling of both arteries and veins (Wang et al., 1998). An
essential feature of this model is that upon engaging EphB4
receptors on veins, ephrinB2 functions as a receptor in arteries.
This idea is supported by studies demonstrating that ephrinB
cytoplasmic domains can undergo phosphorylation upon
receptor binding (reviewed by Adams et al., 2001; Wilkinson,
2000; Mellitzer et al., 1999; Xu et al., 1999; Bruckner et al.,
1997; Holland et al., 1996). Furthermore, a knockout of the
ephrinB2 intracellular domain shows that the cytoplasmic tail
of ephrinB2 is required for vascular morphogenesis (Adams et
al., 2001). These data, and the fact that the Ephb4 mutation
causes arterial as well as venous defects, suggest a requirement
for reciprocal signaling by Eph receptors to ephrinB2 in
vascular remodeling. Our results take this one step further,
showing that, in fact, this reverse signal must be received by
arterial endothelial cells and/or endocardial cells for
angiogenesis to occur. Taken together, these data reinforce the
idea that bi-directional signaling between ephrinB2 and EphB4
in the cardiovascular system is essential for angiogenesis
(Wang et al., 1998). 
Recent publications have highlighted the fact that many
ephrins and Eph receptors are expressed in and around the adult
vasculature at sites of active angiogenesis such as wound-
healing and tumor angiogenesis, both in mice (Gale et al.,
2001; Shin et al., 2001) and humans (reviewed by Takai et al.,
2001; Dodelet and Pasquale, 2000; Ogawa et al., 2000; Berclaz
et al., 1996). These reports hint at potential roles for ephrins
and Ephs in normal and pathological angiogenesis in the adult.
Establishing whether the adult expression patterns of these
S. S. Gerety and D. J. Anderson
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ligands and receptors reflect functional roles in these
angiogenic events will be an important step in determining the
potential relevance of ephrin/Eph targeting drugs for pro- or
anti-angiogenic therapies of cardiovascular disease and cancer,
respectively. Our study has demonstrated the potential of
conditional knockouts in understanding ephrin function and
expression, and provides a useful mouse model system to
further examine these issues in the adult.
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